In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates

Journal of Controlled Release

Volumn 68, Issue 3, 2000, Pages 419-431

  Yoo, Hyuk Sang ^a   Lee, Keun Hyeung ^b   Oh, Jong Eun ^b   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Mogam Biotechnology Research Institute   (South Korea)

Author keywords

Anti cancer therapy; Conjugation; Doxorubicin; PLGA; Sustained release

Indexed keywords

DOXORUBICIN; NANOPARTICLE; POLYGLACTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG FORMULATION; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ELECTROCHEMISTRY; LACTIC ACID; MICE; MICROSCOPY, CONFOCAL; MICROSPHERES; NEOPLASM TRANSPLANTATION; POLYGLYCOLIC ACID; POLYMERS; TETRAZOLIUM SALTS; THIAZOLES; THYMOMA; THYMUS NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0000972145     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00280-7     Document Type: Article

References (24)

1. Harris J.M. Topic in Applied Chemistry Poly(ethylene glycol) Chemistry: Biochemical and Biomedical Applications. 1992;1-14 Plenum Press, New York.
2. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Rel. 54:1998;223-233.
3. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-cancer Drugs. 3:1992;175-210.
4. Colin de Verdiere A., Dubernet C., Nemati F., Poupon M.F., Puisieux F., Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug resistant leukemic murine cells. Cancer Chemother. Pharmacol. 33:1994;504-508.
5. Omelyanenko V., Kopeckova P., Gentry C., Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Rel. 53:1998;25-37.
6. Yokoyama M., Kwon G.S., Okano T., Sakurai Y., Seto T., Kataoka K. Preparation of micelle-forming polymer-drug conjugates. Bioconj. Chem. 3:1992;295-301.
7. Yoo H.S., Oh J.E., Lee K.H., Park T.G. Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release. Pharm. Res. 16:1999;1114-1118.
8. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Sys. 6:1989;193-210.
9. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. CRC Crit. Rev. Ther. Drug Carrier Sys. 9:1992;132-187.
10. Heuser L.S., Miller F.N. Differential macromolecular leakage from the vasculature of tumors. Cancer. 57:1986;461-464.
11. Yokoyama M., Kwon G.S., Okano T., Sakurai Y., Seto T., Kataoka K. Preparation of micelle-forming polymer-drug conjugates. Bioconj. Chem. 3:1992;295-301.
12. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta. 1070:1991;187-192.
13. Stolink S., Illum L., Davis S.S. Long circulating microparticulate drug carriers. Adv. Drug. Deliv. Rev. 16:1995;195-214.
14. Couvreur P., Vauthier C. Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. J. Control. Rel. 17:1991;187-198.
15. Tabata Y., Murakami Y., Ikada Y. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Rel. 50:1998;123-133.
16. Kreuter J. Nanoparticle-based drug delivery systems. J. Control. Rel. 16:1991;169-171.
17. Maeda H., Ueda M., Morinaga T., Matsumoto T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem. 28:1985;455-461.
18. Oh J.E., Nam Y.S., Lee K.H., Park T.G. Conjugation of drug to poly(D,L-lactic-co-glycolic acid) for controlled release from biodegradable microspheres. J. Control. Rel. 57:1999;269-280.
19. Park T.G. Degradation of poly(D,L-lactic)microsphere: effect of molecular weight. J. Control. Rel. 30:1994;161-173.
20. Reed A.M., Gilding D.K. Biodegradable polymers for use in surgery-poly(glycolic acid)/poly(lactic acid) homo and copolymers. 2. In vitro degradation. Polymer. 22:1981;494-498.
21. Freshney R.I. Measurement of viability and cytotoxicity. Culture of Animal Cells. 3rd Edition :1994;287-307 Wiley-Liss Inc, New York. Chapter 19.
22. Ehrke M.J., Verstovsek S., Ujhazy P., Meer J.M., Eppolito C., Maccubbin D.L., Mihich E. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 MICE. Cancer Immunol. Immunother. 45:1998;287-298.
23. Doppenschmitt S., Langguth H.S., Regardh C.G., Langguth P. Role of p-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive permeability and affinity to p-glycoprotein pump. J. Pharm. Sci. 88:1999;1067-1072.
24. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissues distribution of cytochrome P-450 3A and p-glycoprotein have implications for drug delivery and activity in chemotherapy. Mol. Carcinogen. 13:1995;129-134.